Andon Health Co.Ltd(002432) on the morning of January 27, it was announced that the order of covid-19 kit in the United States was added. Boosted by the news, Andon Health Co.Ltd(002432) opened up rapidly. As of the morning closing, the company’s share price rose 5.84%.
the order amount is increased by $500 million
According to the announcement of Andon Health Co.Ltd(002432) , on January 26 local time in the United States, the U.S. subsidiary signed a change contract with the U.S. ACC (U.S. Army contract management command) on the original purchase contract. On the basis of the purchase of 250 million ihealth kit products in the original contract, 104 million ihealth Kit products were purchased. Due to the above changes, The total contract amount increased from US $1.275 billion to US $1.775 billion, about RMB 11.226 billion. The ihealth kit products purchased additionally shall be delivered before March 14, 2022, and the delivery method shall be Fob origin.
Andon Health Co.Ltd(002432) said that the performance of the above contract will have a positive impact on the operating revenue and operating profit in 2022. But at the same time, it is suggested that during the execution of orders and contracts, there may be a risk that the contract can not be performed on schedule or in full due to the impact of local epidemic changes, policy changes, changes in the company’s supply chain capacity, logistics and transportation risks, the terms that the U.S. government has the right to terminate the contract at any time due to its own factors, as well as unforeseen or force majeure.
Benefiting from the significant increase in sales of the company’s testing kit products in the U.S. market, the company expects a significant increase in performance in 2021. On the evening of January 19, Andon Health Co.Ltd(002432) disclosed the performance forecast for 2021. It is estimated that the net profit attributable to the parent company in 2021 will be RMB 900 million to RMB 1.2 billion, with a year-on-year increase of 271.4% to 395.19%; The net profit deducted from non parent company was 850 million yuan to 1.15 billion yuan, with a year-on-year increase of 243.46% to 364.68%.
The US order is added, and the new contract amount is about 10 times the expected net profit in 2021, or to provide guarantee for the performance in 2022.
the cumulative decline from the high point has been nearly 40%
On the evening of November 7, 2021, Andon Health Co.Ltd(002432) announced that the U.S. subsidiary ihealth home covid-19 self-test kit obtained the emergency use authorization (EUA) of the U.S. Food and Drug Administration (FDA). After that, the company’s share price sat on the “helicopter” and continued to rise the limit, hitting record highs.
After the beginning of 2022, the company’s share price continued to rise sharply. From January 11 to January 17, the company closed five consecutive boards. From the lowest 5.8 yuan on October 29, 2021 to the highest 88.88 yuan on January 18 this year, the cumulative increase of Andon Health Co.Ltd(002432) in two and a half months exceeded 14 times.
Recently, the stock price of Andon Health Co.Ltd(002432) which has soared continuously has been adjusted. From January 18 to January 26, the company’s stock price has fallen by nearly 40% from the high point of 88.88 yuan / share.
